BioSpace News Archive

According to Transparency Market Research’s latest report on the global inhalation and nasal spray generic drugs market for the historical period 2017–2018 and forecast period 2019–2027, increasing prevalence of asthma and COPD disorders, and burgeoning demand for cost-effective generic drugs are projected to drive the global inhalation and nasal spray generic drugs market during the forecast period

The significant rise in the prevalent of chronic diseases across the world, including the increasing incidence of cardiovascular diseases, which need early detection, is influencing the global market for venipuncture procedure analysis significantly.

In case of injury, trauma, or defect in the lower extremities of the body, i.e. the feet and ankles, special plates and screws are available for use to rectify and reconstruct them.

Data Showcase Promising Safety and Efficacy for Investigational Multiple Sclerosis Therapy and Importance of Addressing Fatigue Symptoms

Transparency Market Research has published a new report on the life science reagents market for the forecast period of 2019–2027.

Transparency Market Research has published a new report titled, ‘Dental Practice Management Software Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027’.

Miracor Medical SA has announced the closing of a 24M€ Series-E round of financing. The round was led by a new corporate strategic investor joined by co-investor Yonghua.

Vertically placed, circumferential sutures expand the possibilities of meniscal repair to include Horizontal Cleavage, Radial, Complex and Root tear patterns

Immunovia AB a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced that Dr. Peter Schultz-Knappe, Chief Technology Officer, is stepping down from his position to pursue other opportunities effective on August 31, 2020.

POXEL SA announced the initiation of DESTINY 1 Efficacy and Safety Trial In NASH), the single dose-ranging Phase 2 trial evaluating PXL065 for the treatment of NASH.